インフルエンザワクチン市場：ワクチンタイプ別、年齢層別、投与経路別、流通チャネル別-2025-2030年の世界予測

インフルエンザワクチン市場は、2023年に79億2,000万米ドルと評価され、2024年には86億1,000万米ドルに達すると予測され、CAGR 9.01％で成長し、2030年には144億9,000万米ドルに達すると予測されています。

インフルエンザワクチン市場は、インフルエンザウイルスの蔓延を防ぐためのワクチンの開発、生産、流通を包括しています。この市場は、世界的に重大な健康課題をもたらしている季節性インフルエンザの発生を抑制する必要性によって牽引されています。主な用途は、政府の保健部門、ヘルスケア施設、民間クリニックが運営する予防接種プログラムであり、最終用途はあらゆる年齢層の個人、特に高齢者、幼児、免疫力が低下している人など脆弱な人々に及ぶ。成長に影響を与える主な要因としては、インフルエンザ・ワクチン接種プログラムに対する政府および民間投資の増加、ワクチン技術の継続的進歩、季節性インフルエンザが健康に及ぼす影響に対する意識の高まりなどが挙げられます。市場開拓の機会としては、新興国市場の拡大、幅広い予防効果を提供する4価ワクチンへの需要の高まり、注射針を使わないワクチン投与などの革新的な投与方法が挙げられます。これらを活用するため、企業はより効果的で保護期間が長いワクチンの開発や、ワクチン接種率を高めるための教育キャンペーンの拡大に注力すべきです。しかし、市場の成長は、ワクチン接種のためらい、高い研究開発コスト、効果的なワクチン処方のための将来のインフルエンザ株の予測の複雑さといった課題に直面しています。また、規制上のハードルやジェネリックメーカーとの競合による限界も生じています。mRNA技術の利用、ワクチン保存ソリューションの強化、迅速なワクチン製造方法の改善といった分野における技術革新は、大きな進歩をもたらす可能性があります。結局のところ、この市場の特徴は、インフルエンザ株の変異が繰り返され、常に最新のワクチンが必要とされるダイナミックな性質にあり、製品の差別化と市場浸透のための継続的な機会を提供しています。こうした側面を理解することで、この分野の企業は、持続可能な事業成長を促進するための課題と機会を戦略的にナビゲートすることができます。

市場力学：急速に進化するインフルエンザワクチン市場の主要市場インサイトを公開

インフルエンザワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 呼吸器疾患の有病率の増加
  • インフルエンザウイルス感染予防のための主要な公衆衛生対策としての予防接種
  • 季節性インフルエンザを対象とした臨床試験とワクチン開発のパイプライン
  • 呼吸器の健康を支援する政府の取り組み
• 市場抑制要因
  • 不十分な医療インフラと限られた認知度
• 市場機会
  • 大手企業による研究開発費の増加
  • 流通と開発協力によるワクチン入手の増加
  • 動物インフルエンザAウイルスに対する複数のワクチン候補が開発中
• 市場の課題
  • 呼吸器疾患ワクチン接種に対する顧客の信頼と信用
  • ワクチン研究開発は、常に変動する株によって課題となっています。

ポーターの5つの力：インフルエンザワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：インフルエンザワクチン市場における外部からの影響の把握

外部マクロ環境要因は、インフルエンザワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析インフルエンザワクチン市場における競合情勢の把握

インフルエンザワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスインフルエンザワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、インフルエンザワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨インフルエンザワクチン市場における成功への道筋を描く

インフルエンザワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 呼吸器疾患の罹患率の増加
    • インフルエンザウイルス感染予防のための主要な公衆衛生対策としての予防接種
    • 季節性インフルエンザの臨床試験とワクチン開発が進行中
    • 呼吸器の健康を支援する政府の取り組み
  • 抑制要因
    • 不十分な配信インフラと限られた認知度の欠如
  • 機会
    • 大手市場プレーヤーによる研究開発費の増加
    • 流通と開発の連携によるワクチンの入手可能性の向上
    • 動物インフルエンザAウイルスに対する複数のワクチン候補が開発中
  • 課題
    • 呼吸器疾患ワクチンに対する顧客の信頼と自信
    • ワクチンの研究開発は、株の絶え間ない変化によって困難に直面している
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 インフルエンザワクチン市場ワクチンの種類別

• 不活性化
• 生ワクチン
• 組み換え

第7章 インフルエンザワクチン市場：年齢層別

• 青少年の予防接種
• 成人の予防接種
• 乳児の予防接種

第8章 インフルエンザワクチン市場投与経路別

• 筋肉内
• 鼻腔内
• オーラル

第9章 インフルエンザワクチン市場：流通チャネル別

• 政府医療事務所
• 病院・クリニック
• 小売薬局
• 緊急治療室

第10章 南北アメリカのインフルエンザワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のインフルエンザワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのインフルエンザワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AstraZeneca PLC
• Bayer AG
• BioDiem
• BiondVax Pharmaceuticals Ltd.
• Bristol-Myers Squibb Company
• CanSino Biologics Inc.
• Daiichi Sankyo Company, Limited
• Emergent BioSolutions Inc.
• Eurocept Group
• Fluart Innovative Vaccines Kft.
• Gamma Vaccines Pty Ltd
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi S.A.
• Seqirus GmbH
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Swedish Orphan Biovitrum AB

LIST OF FIGURES

• FIGURE 1. INFLUENZA VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. INFLUENZA VACCINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFLUENZA VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFLUENZA VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. CANADA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 39. CANADA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 61. CHINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. INDIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 65. INDIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. ITALY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 134. ITALY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. POLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 150. POLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. QATAR INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 154. QATAR INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

The Influenza Vaccine Market was valued at USD 7.92 billion in 2023, expected to reach USD 8.61 billion in 2024, and is projected to grow at a CAGR of 9.01%, to USD 14.49 billion by 2030.

The influenza vaccine market encompasses the development, production, and distribution of vaccines designed to prevent the spread of influenza viruses. This market is driven by the necessity to control seasonal flu outbreaks, which result in significant health challenges globally. The primary applications include immunization programs run by government health departments, healthcare facilities, and private clinics, while the end-use scope extends to individuals across all age groups, especially vulnerable populations such as the elderly, young children, and those with weakened immune systems. Key influencing growth factors include increased government and private investments in flu vaccination programs, continuous advancements in vaccine technology, and heightened awareness about seasonal influenza's health impacts. Opportunities within the market are notably led by emerging markets in developing nations, rising demand for quadrivalent vaccines offering broader protection, and innovative delivery methods such as needle-free vaccine administrations. To capitalize on these, businesses should focus on developing more effective vaccines with longer durations of protection and expanding educational campaigns to boost vaccination rates. However, market growth faces challenges like vaccine hesitancy, high research and development costs, and the complexity of predicting future influenza strains for effective vaccine formulation. Limitations also arise from regulatory hurdles and competition from generic manufacturers. Innovating in areas such as the use of mRNA technology, enhancing vaccine storage solutions, and improving rapid vaccine production methods could drive significant advancements. Ultimately, the market is characterized by its dynamic nature, necessitated by recurring influenza strain mutations and the constant requirement for updated vaccines, providing ongoing opportunities for product differentiation and market penetration. Understanding these facets, companies in the sector can strategically navigate the challenges and opportunities to drive sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Vaccine Market

The Influenza Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Prevalence of Respiratory Disorders
  • Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
  • Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
  • Government Initiatives Supporting Respiratory Health
• Market Restraints
  • Lack of Inadequate Delivery Infrastructure & Limited Awareness
• Market Opportunities
  • Increasing R&D Expenditure by Leading Market Players
  • Increasing Vaccine Availability through Distribution and Development Collaborations
  • Several Vaccine Candidates under Development against Animal Influenza A Virus
• Market Challenges
  • Customers Trust and Confidence in Respiratory Disease Vaccination
  • Vaccine Research and Development are getting Challenged by the Constant Variations in Strains

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Vaccine Market

A detailed market share analysis in the Influenza Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Vaccine Market

A strategic analysis of the Influenza Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Vaccine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, BioDiem, BiondVax Pharmaceuticals Ltd., Bristol-Myers Squibb Company, CanSino Biologics Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Eurocept Group, Fluart Innovative Vaccines Kft., Gamma Vaccines Pty Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus GmbH, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Swedish Orphan Biovitrum AB.

Market Segmentation & Coverage

This research report categorizes the Influenza Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Vaccine Type, market is studied across Inactivated, Live Attenuated, and Recombinant.
• Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
• Based on Administration Route, market is studied across Intramuscular, Intranasal, and Oral.
• Based on Distribution Channel, market is studied across Government Medical Office, Hospital & Clinic, Retail Pharmacy, and Urgent Care Unit.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence of Respiratory Disorders
    • 5.1.1.2. Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
    • 5.1.1.3. Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
    • 5.1.1.4. Government Initiatives Supporting Respiratory Health
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of Inadequate Delivery Infrastructure & Limited Awareness
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing R&D Expenditure by Leading Market Players
    • 5.1.3.2. Increasing Vaccine Availability through Distribution and Development Collaborations
    • 5.1.3.3. Several Vaccine Candidates under Development against Animal Influenza A Virus
  • 5.1.4. Challenges
    • 5.1.4.1. Customers Trust and Confidence in Respiratory Disease Vaccination
    • 5.1.4.2. Vaccine Research and Development are getting Challenged by the Constant Variations in Strains
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Influenza Vaccine Market, by Vaccine Type

• 6.1. Introduction
• 6.2. Inactivated
• 6.3. Live Attenuated
• 6.4. Recombinant

7. Influenza Vaccine Market, by Age Group

• 7.1. Introduction
• 7.2. Adolescent Vaccination
• 7.3. Adult Vaccination
• 7.4. Infant Vaccination

8. Influenza Vaccine Market, by Administration Route

• 8.1. Introduction
• 8.2. Intramuscular
• 8.3. Intranasal
• 8.4. Oral

9. Influenza Vaccine Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Government Medical Office
• 9.3. Hospital & Clinic
• 9.4. Retail Pharmacy
• 9.5. Urgent Care Unit

10. Americas Influenza Vaccine Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Influenza Vaccine Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Influenza Vaccine Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AstraZeneca PLC
• 3. Bayer AG
• 4. BioDiem
• 5. BiondVax Pharmaceuticals Ltd.
• 6. Bristol-Myers Squibb Company
• 7. CanSino Biologics Inc.
• 8. Daiichi Sankyo Company, Limited
• 9. Emergent BioSolutions Inc.
• 10. Eurocept Group
• 11. Fluart Innovative Vaccines Kft.
• 12. Gamma Vaccines Pty Ltd
• 13. GlaxoSmithKline PLC
• 14. Johnson & Johnson
• 15. Merck & Co., Inc.
• 16. Pfizer Inc.
• 17. Sanofi S.A.
• 18. Seqirus GmbH
• 19. Serum Institute of India Pvt. Ltd.
• 20. Sinovac Biotech Ltd.
• 21. Swedish Orphan Biovitrum AB